179 related articles for article (PubMed ID: 37865876)
1. Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells.
Sayadmanesh A; Azadbakht M; Yari K; Abedelahi A; Shafaei H; Shanehbandi D; Baradaran B; Basiri M
Cell J; 2023 Oct; 25(10):674-687. PubMed ID: 37865876
[TBL] [Abstract][Full Text] [Related]
2. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.
Yang LR; Li L; Meng MY; Wang WJ; Yang SL; Zhao YY; Wang RQ; Gao H; Tang WW; Yang Y; Yang LL; Liao LW; Hou ZL
J Cell Mol Med; 2021 Jan; 25(2):686-700. PubMed ID: 33225580
[TBL] [Abstract][Full Text] [Related]
4. Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice.
Li J; Zhou W; Li D; Huang Y; Yang X; Jiang L; Hu X; Yang J; Fu M; Zhang M; Wang F; Li J; Zhang Y; Yang Y; Yan F; Gao H; Wang W
Cancer Lett; 2023 Aug; 568():216287. PubMed ID: 37392990
[TBL] [Abstract][Full Text] [Related]
5. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
[TBL] [Abstract][Full Text] [Related]
6. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
7. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
8. [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].
Peng YJ; Wu QY; Liu HY; Zhao J; Wei HF
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):581-587. PubMed ID: 28539278
[TBL] [Abstract][Full Text] [Related]
9. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
11. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
[TBL] [Abstract][Full Text] [Related]
12. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.
Shrestha B; Zhang Y; Yu B; Li G; Boucher JC; Beatty NJ; Tsai HC; Wang X; Mishra A; Sweet K; Lancet JE; Kelley L; Davila ML
J Immunother; 2020 Apr; 43(3):79-88. PubMed ID: 31834208
[TBL] [Abstract][Full Text] [Related]
13. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
Huls MH; Figliola MJ; Dawson MJ; Olivares S; Kebriaei P; Shpall EJ; Champlin RE; Singh H; Cooper LJ
J Vis Exp; 2013 Feb; (72):e50070. PubMed ID: 23407473
[TBL] [Abstract][Full Text] [Related]
15. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
18. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
19. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.
Ye Q; Loisiou M; Levine BL; Suhoski MM; Riley JL; June CH; Coukos G; Powell DJ
J Transl Med; 2011 Aug; 9():131. PubMed ID: 21827675
[TBL] [Abstract][Full Text] [Related]
20.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
